去卵巢大鼠骨密度变化与骨髓组织血管生成的关系

目的： 探讨去卵巢大鼠骨密度变化与骨髓组织血管生成的关系。方法：30只SD雌性大鼠随机分为去卵巢组（OVX）和假手术组（sham）,分别在4周、8周和12周处死。取左侧股骨测量骨密度(BMD)。右侧远端股骨干骺端松质骨甲醛固定,EDTA-Na2脱钙。常规脱水、石蜡包埋、切片。行苏木素－伊红染色用于观察骨髓组织病理改变,用CD34标记血管内皮细胞观察微血管密度(MVD),采取大鼠腹主动脉血进行血管内皮生长因子(VEGF)测定。结果： 大鼠去卵巢8周后BMD明显低于假手术组, 提示骨质疏松模型建立,此时,骨髓造血组织容量减少,脂肪组织容量增高,与假手术组比较均有显著差异（P<0.01）,骨髓组织MVD与假手术组比略有减少。12周后,上述改变更为明显。同时,骨小梁容量减少,骨髓组织MVD明显减少（P<0.05）,且显示MVD与BMD、造血组织容量和骨小梁容量呈正相关,与脂肪组织容量呈负相关。但血浆VEGF含量测定OVX组与sham组间无明显差异,与骨髓组织各形态指标亦无相关性。结论：去卵巢大鼠在骨量丢失和造血组织容量减少的同时伴有骨髓组织MVD减少, 为骨质疏松症采用促微血管增生治疗提供了实验依据。     

磁场对去卵巢大鼠骨密度、骨强度和骨代谢的影响

本文研究了旋转恒定磁场对去卵巢大鼠骨密度，骨强度和骨代谢的影响。结果表明磁场处理30分钟且加钙组的骨密度，能量吸收，弹性能量吸收，最大载荷，最大桡度和弹性桡度等指标均显著高于去卵巢组，分别增加3.5%,15.4%,12.4%,7.6%,5.8%,11.9%t 5.2%。其碱性磷酸酶，血磷，血钙等指标也比去卵巢组分别高71％，108％，156％。实验还检测了暴磁1个月及停止暴磁后1到2个月，大鼠骨密度和骨矿含量的变化，结果表明磁场处理存在着窗口效应和滞后效应。     

丹皮酚对去卵巢骨质疏松大鼠叉头框蛋白O3a/Wnt信号通路及椎骨密度的影响

背景:丹皮酚可抑制炎症,减轻慢性骨关节炎临床症状,作为一种不良反应小、更为安全的天然药物成分,探讨其对骨质疏松症的治疗作用具有重要的临床意义。目的:探究丹皮酚对去卵巢骨质疏松大鼠叉头框蛋白O3a(forkhead box O3a,FoxO3a)/Wnt信号通路及椎骨密度的影响。方法:雌性SD大鼠随机分为6组,每组10只。假手术组仅切除卵巢旁部分脂肪组织;其余50只大鼠均采用双侧卵巢摘除法制备去卵巢骨质疏松大鼠模型,模型制备成功后分为模型组、雌激素组[炔雌醇10μg/(kg·d)]、丹皮酚低、中、高剂量组[丹皮酚125,250,500 mg/(kg·d)],每组10只,灌胃给药;假手术组、模型组灌胃等量生理盐水,持续干预12周。ELISA法测定血清雌激素、骨保护素、骨钙素水平;采用双能X射线动物骨密度测定仪检测大鼠股骨及椎骨骨密度;采用骨科生物力学测试仪检测大鼠股骨及椎骨生物力学指标:弹性模量、最大载荷、屈服载荷;实时荧光定量PCR检测椎骨组织FoxO3a、Wnt2 mRNA表达水平;免疫印迹法检测椎骨组织FoxO3a、Wnt2及核内β-catenin蛋白表达。结果与结论:①治疗后,与假手术组比较,模型组L4,5骨密度、弹性模量、最大载荷、屈服载荷、血清雌二醇、骨保护素水平、椎骨组织Wnt2 mRNA及蛋白水平、核内β-catenin蛋白水平均显著降低(P<0.05),骨钙素水平、椎骨组织FoxO3a mRNA及蛋白水平显著增加(P<0.05);②与模型组比较,丹皮酚低、中、高剂量组大鼠L4,5骨密度、弹性模量、最大载荷、屈服载荷、血清雌二醇、骨保护素水平、椎骨组织Wnt2 mRNA及蛋白水平、核内β-catenin蛋白水平依次增加(P<0.05),血清骨钙素水平、椎骨组织FoxO3a mRNA及蛋白水平依次降低(P<0.05),且丹皮酚高剂量组均优于雌激素组(P<0.05);③提示丹皮酚可增加去卵巢骨质疏松大鼠椎骨骨密度,改善其骨生物力学状况,减轻骨质疏松,该作用可能与抑制FoxO3a、促进Wnt2/β-catenin通路激活有关。     

补肾壮骨方干预去卵巢骨质疏松模型大鼠骨代谢及骨密度的变化

背景：中医药以其良好的治疗效果及安全性越来越多的应用于骨质疏松症的治疗中,补肾壮骨方目前作为山东中医药大学附属医院协定方被广泛应用于临床中,获得了极好的治疗效果。目的：评价补肾壮骨方对去卵巢骨质疏松大鼠骨代谢及骨密度的影响。方法：60只SD大鼠随机分为6组,分别为假手术组、模型组、阿仑膦酸钠组、补肾壮骨方高、中、低剂量组,每组10只,后5组制备去卵巢骨质疏松症模型,假手术组只切除卵巢周围脂肪组织。造模8周后,补肾壮骨方高、中、低剂量组分别予以2.34,1.17,0.58 g/(kg·d)补肾壮骨方,阿仑膦酸钠组予阿仑膦酸钠1 mg/(kg·d),假手术组及模型组给予等体积的生理盐水,1次/d灌胃。连续灌胃12周后检测各组大鼠血清碱性磷酸酶、Runt相关转录因子2及核因子κB受体活化因子配体水平;取右侧股骨观察骨密度及骨微结构;苏木精-伊红染色观察组织病理改变;免疫组化法检测骨组织Wnt1、骨形态发生蛋白2蛋白表达。结果与结论：(1)造模8周后,与假手术组对比,模型组大鼠骨密度、骨小梁数明显降低(P <0.05),提示造模成功;(2)与模型组大鼠对比,补肾壮骨方低、中、高剂量组及阿...     

龟鹿胶、淫羊藿及红景天对骨质疏松大鼠骨密度及破骨细胞的影响

背景：中药研究骨质疏松症目前缺乏系统的药效学研究,中药组方尚欠精简,机制研究与中医理论指导不够紧密。 目的：观察中药复方龟鹿胶、淫羊藿、红景天对去卵巢大鼠血清各指标、骨密度及破骨细胞的的调控作用。 方法：建立去卵巢大鼠模型,分别用自拟中药组方龟鹿胶组、淫羊藿组、红景天组进行灌胃,以假手术组和模型组进行对比。造模后第4周开始称体质量,每周1次。造模后12周后测定大鼠骨密度、血清中钙、磷含量、血碱性磷酸酶活性等指标比较治疗效果,应用体外培养破骨细胞观察各组中药对破骨细胞抑制率的影响。 结果与结论：龟鹿胶能显著减少去卵巢大鼠体质量的增加幅度(P < 0.05)。相比模型组3种中药治疗组大鼠血清中钙含量明显升高(P < 0.05),血磷与碱性磷酸酶活性明显降低(P < 0.01或P < 0.05)。龟鹿胶组和淫羊藿组大鼠骨密度显著高于模型组(P < 0.05)。3种中药治疗组与假手术组相比吸收陷窝数明显减少(P < 0.05),其中红景天组吸收陷窝数减少较显著(P < 0.01),红景天组对破骨细胞吸收功能具有抑制作用,抑制率为86.85%(P < 0.01)。结果证实,中药组方龟鹿胶、淫羊藿、红景天对去卵巢骨质疏松均具有显著疗效,其中龟鹿胶组和淫羊藿组主要以增加骨密度为主,红景天组具体表现在对破骨细胞吸收功能具有抑制作用。     

A long-term study of bone mineral density in patients with phenylketonuria under diet therapy

Introduction

Dietary control of classic phenylketonuria (PKU) needs restriction of natural proteins; adequate protein intake is achieved by adding low phenylalanine (phe) formulae. The adequacy of this diet for normal bone mineralization had not been sufficiently evaluated. Our aim was to evaluate and follow up bone mineral density (BMD) in children and adolescents with PKU within a 2-year time interval to assess the adequacy of a phenylalanine restricted diet for bone mineralization and to search for a possible relationship between BMD, dietary control and blood phenylalanine (phe) concentrations.

Material and methods

Thirty-two patients with classic PKU (3-19 years) were evaluated for their bone mineral status using dual energy X-ray absorptiometry (DEXA) both at the beginning (baseline) and the end (follow-up) of the study.

Results

Low BMD was detected in 31.25% at the start and in 6.25% of patients after 2 years follows-up. No relationship was found between BMD and the duration of diet compliance and phe level as well.

Conclusions

In this study the low BMD detected in our patients was both at baseline and follow-up independent of diet restriction. A yearly DEXA would be highly beneficial for early detection and treatment, thus preventing osteoporosis and decreasing the risk of fractures. We also suggest the importance of searching for new emerging therapies such as enzyme substitution or gene therapy as low protein diet compliance was not enough to maintain normal bone mineral density.     

类固醇激素对大鼠股骨及腰椎的骨密度影响

目的：探讨类固醇激素对大鼠股骨和腰椎的骨密度影响。方法：雄性SD大鼠分为基础对照组、实验对照组和激素模型组；用DEXA对各组的离体双侧股骨和第5腰椎进行骨密度测定。结果：与实验对照组比较，激素模型组股骨和第5腰椎的总骨密度减少了14．77％；腰椎的骨密度减少了23．00％；左、右股骨远段的骨密度分别减少了19．83％、21．37％，具显著或非常显著差异。结论：长期使用类固醇激素，会使大鼠的骨量丢失，尤以松质骨的丢失比密质骨更为明显。故出现骨质疏松时，松质骨更容易出现骨折。     

广西瑶族中老年人骨密度与体成分的相关性分析

目的:分析探讨广西瑶族中老年人身高、体质量、脂肪率、脂肪、体质量指数与骨密度的规律及其相关性。方法:随机抽取343名(男性123名,女性220名)广西瑶族健康中老年人作为研究对象,检测受试者的体质量、脂肪率、脂肪量、体质量指数、身高和右足跟骨密度。结果:广西瑶族中老年人身高、体质量、脂肪率、脂肪量、体质量指数与骨密度均随着年龄的增长逐渐降低,不同性别间身高、脂肪率和骨密度差异明显。男性的身高、脂肪率和骨密度均大于同龄段女性,男性骨密度减少的幅度小于女性。男、女性的身高、体质量、体质量指数与骨密度均显著相关。结论:广西瑶族中老年人身高、体质量、体质量指数和骨密度随年龄的增长逐渐降低,且身高、体质量、体质量指数对骨密度起决定性作用。     

甲状旁腺素和二膦酸盐对骨密度和骨生物力学的影响

目的:研究应用甲状旁腺素和阿仑膦酸钠对激素性骨质疏松兔骨密度和生物力学的影响。方法:采用成年新西兰大白兔,随机分为对照组、激素模型组、甲状旁腺素和阿仑膦酸钠治疗组,9周后取股骨和腰椎行超声骨密度测量,再行股骨扭转、三点弯曲和腰椎压缩试验。结果:激素模型组的宽频超声衰减(BUA)、超声传导速度(SOS)值和骨生物力学参数较对照组有非常明显减少,甲状旁腺素和阿仑膦酸钠治疗组的BUA、SOS值和骨生物力学参数较激素模型组明显增加。结论:序贯应用甲状旁腺素和阿仑膦酸钠可以减少激素性兔骨量的丢失,预防骨质疏松的发生。     

Histopathology of bone marrow reconstitution after allogeneic bone marrow transplantation

In order to study haematopoietic reconstitution in allogeneic bone marrow transplantation we investigated bone marrow histology in 61 biopsies of 37 patients, treated with HLA-compatible bone marrow grafts for leukaemia or severe aplastic anaemia. The biopsies were taken from the day of transplantation until 100 d after transplantation. Stromal changes, in particular oedema, fibrosis and granulomas, were found during the whole period of observation. These changes were more prominent in biopsies from leukaemia patients than from patients with aplastic anaemia. The cellularity in the biopsies increased until 28 d after bone marrow transplantation and was stable thereafter. Initially, only clusters of cells belonging to a single cell lineage were seen, suggesting that the first outgrowth of haematopoietic cells is by proliferation of committed precursor cells. Long-lasting abnormalities in localization of haematopoietic cells in the bone marrow space and of the myeloid: erythroid ratio were seen; dyserythropoiesis was common.     

Multifactorial analysis of risk factors for reduced bone mineral density among postmenopausal women

Introduction

The study aimed to determine the risk factors for reduced bone mineral density (BMD) among postmenopausal women.

Material and methods

Two hundred and fifty-three postmenopausal women were included to the study. The study group consisted of 85 women with osteoporosis (mean age: 59.9 years) and 168 with osteopenia (mean age: 57.8 years). Patients were assigned to groups according to their BMD measured in the lumbar spine, hip and femoral neck by dual X-ray absorptiometry. Bone formation was assessed by measuring serum osteocalcin and bone resorption by measuring serum C-terminal type I α-collagen chain telopeptide.

Results

Multiple regression analysis for lumbar spine showed association of age (p = 0.001), parental history of fracture (p = 0.05), use of hormone replacement therapy (p = 0.034), bisphosphonates therapy (p < 0.001), calcium and vitamin D supplements therapy (p = 0.001), oestradiol level (p = 0.007) and body mass index (p < 0.001). Multiple regression analysis for femoral neck and hip total showed association of age (p = 0.001), parental history of fracture (p = 0.049), use of bisphosphonates (p < 0.03)) use of calcium and vitamin D supplements (p = 0.039), oestradiol level (p = 0.047). All the variables together explain 40.4% of variance in BMD for the lumbar spine and 25.6% of variance in BMD for femoral neck and hip total.

Conclusions

The present study demonstrated correlations between the variables and BMD, which are known and widely described in the literature. Osteoporosis and osteopenia in Polish subjects appear to be associated with several known risk factors that are well described in the literature.     

Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis

The purpose of this open-labeled prospective study was to compare the treatment effects of cyclical etidronate and alendronate on the lumbar bone mineral density (BMD), bone resorption, and back pain in elderly women with osteoporosis. Fifty postmenopausal women with osteoporosis, age ranging from 55 to 86 years (mean: 70.7 years), were randomly divided into two groups with 25 patients in each group: the cyclical etidronate group (etidronate 200 mg daily for 2 weeks every 3 months) and the alendronate group (5 mg daily). The BMD of the lumbar spine (L1-L4) measured by DXA, the urinary cross-linked N-terminal telopeptides of type I collagen (NTX) level measured by the enzyme-linked immunosorbent assay, and back pain evaluated by the face scale score were assessed at baseline, 6 months, and 12 months. There were no significant differences in baseline characteristics including age, body mass index, years since menopause, lumbar BMD, urinary NTX level, and face scale score between the two treatment groups. Etidronate treatment sustained the lumbar BMD following a reduction in the urinary NTX level and improved back pain, while alendronate treatment reduced the urinary NTX level more significantly, resulting in an increase in the lumbar BMD, and similarly improved back pain. No serious adverse events were observed in either group. This study confirmed that alendronate treatment had a greater efficacy than etidronate treatment in increasing the lumbar BMD through the reduction of bone resorption in elderly women with osteoporosis.     

广西罗城仫佬族中老年人跟骨超声骨密度检测分析

目的:调查广西罗城仫佬族中老年人骨密度,探讨该人群骨质疏松(OP)发病率及影响因素。方法:随机抽取45岁以上广西罗城世居仫佬族中老年健康人群,测量其跟骨超声骨密度,身高、体质量、体质量指数(BMI)。测试对象每5岁为1组,分析每组骨密度、骨质疏松患病率及相关影响因素。采用SPSS 17.0软件对数据进行分析。结果:罗城仫佬族中老年骨密度随年龄增长而降低。男性75以上年龄组与45岁年龄组对比差异有统计学意义,女性55岁以上各个年龄组与45岁年龄组对比差异有统计学意义,70岁年龄组,75岁以上年龄组与其余年龄组相比BUA值差异有统计学意义。从45岁年龄组至75岁以上年龄组,骨质疏松发生率在男性由0增至19%,女性则由0增至50%。骨密度与年龄呈负相关,与身高、体质量、BMI呈正相关。结论:罗城仫佬族男性骨密度降低程度较女性平缓。男性在75岁之后,女性55岁之后骨密度下降明显,发生时间早于男性。在该人群中倡导健康生活方式,积极干预,及早诊治对于防治骨质疏松具有重要意义。     

Evidence of bone marrow downregulation in brain‐dead rats

Experimental findings support the evidence of a persistent leucopenia triggered by brain death (BD). This study aimed to investigate leucocyte behaviour in bone marrow and blood after BD in rats. BD was induced using intracranial balloon catheter inflation. Sham‐operated (SH) rats were trepanned only. Thereafter bone marrow cells were harvested every six hours from the femoral cavity and used for total and differential counts. They were analysed further by flow cytometry to characterize lymphocyte subsets, granulocyte adhesion molecules expression and apoptosis/necrosis [annexin V/propidium iodide (PI) protocol]. BD rats exhibited a reduction in bone marrow cells due to a reduction in lymphocytes (40%) and segmented cells (45%). Bone marrow lymphocyte subsets were similar in BD and SH rats (CD3, P = 0.1; CD4, P = 0.4; CD3/CD4, P = 0.4; CD5, P = 0.4, CD3/CD5, P = 0.2; CD8, P = 0.8). Expression of L‐selectin and beta₂‐integrins on granulocytes did not differ (CD11a, P = 0.9; CD11b/c, P = 0.7; CD62L, P = 0.1). There were no differences in the percentage of apoptosis and necrosis (Annexin V, P = 0.73; PI, P = 0.21; Annexin V/PI, P = 0.29). In conclusion, data presented suggest that the downregulation of the bone marrow is triggered by brain death itself, and it is not related to changes in lymphocyte subsets, granulocyte adhesion molecules expression or apoptosis and necrosis.     

中药复方对成骨细胞增殖及骨密度的影响

背景：复方中药是由多种矿物植物动物等物质组成的复方药物,在治疗骨代谢疾病方面,能通过多途径,多靶点发挥综合治疗作用。 目的：研究复方中药对成骨细胞增殖及骨密度的影响,探讨复方中药对骨质疏松症的药理作用。 方法：回顾性分析以往经实验研究证实的某些复方中药对骨质疏松症动物模型成骨细胞增殖分化及骨密度的影响,分析影响复方中药促进骨形成的因素,通过对成骨细胞体外培养方法进行筛选,找出促进细胞增殖分化、提高骨密度的药物适宜剂量,与化学药物结果进行对照研究。 结果与结论：复方中药能够促进成骨细胞增殖分化、提高骨密度,在治疗骨质疏松症方面具有标本兼治、毒副作用小等优点,但复方中药在改善骨密度水平方面不及化学药物,并且应通过长期、大样本的临床研究,降低骨质疏松性骨折风险的干预作用。     

体脂对DXA骨密度测量结果及骨质疏松诊断的影响

随着社会老龄化和生活水平提高,制约老年人健康长寿的骨质疏松症受到越来越多的重视。双能Ｘ线吸收测量法(dual energy X-ray absorptiometer,DXA)测量骨密度是诊断骨质疏松的金标准,但它的精确性受身体脂肪含量的影响。体脂可以干扰DXA测量骨密度的结果,这可能会导致体脂分布改变显著者（如绝经后体脂分布变化较大的女性）骨质疏松诊断的偏倚,造成此类人群骨质疏松时误诊或漏诊的发生。本文就脂肪对骨密度测量结果及骨质疏松诊断的影响作一综述。     

抗阻训练干预绝经后骨质疏松患者骨密度的系统综述和Meta分析

背景:抗阻训练已经被证实对于改善绝经后妇女骨质疏松患者的骨密度有所帮助,但抗阻运动的运动方式、训练强度、训练时间、训练频率,以及与不同运动(有氧运动等)方式的结合是否效果更好还有待研究。目的:评价抗阻训练对绝经后妇女骨质疏松患者骨密度的干预效果。方法:搜集抗阻训练干预绝经后妇女骨质疏松患者骨密度的相关随机对照试验,研究对象分为抗阻训练组及空白对照组,检索Pub Med、EMBASE、Web of Science、中国知网和万方医学数据库,检索的时间范围从建库到2019年12月,并且对纳入文献的相关参考文献进行检索。由2名研究者按纳入和排除标准筛选文献并提取有效数据,进行质量评价。采用Rev Man 5.3软件对最终纳入的文献数据进行Meta分析。结果与结论:①最终纳入23篇随机对照试验,对纳入的文献进行风险偏倚评价,结果显示整体文献质量为中等偏上;②Meta分析结果显示,与空白对照组相比,抗阻训练组可显著改善绝经后妇女骨质疏松患者的腰椎骨密度[SMD=0.02,95%CI(0.01,0.03),P<0.0001]、全髋骨密度[SMD=0.25,95%CI(0.06,0.44),P=0.03]、股骨颈骨密度[SMD=0.28,95%CI(0.12,0.04),P=0.0005]及大转子骨密度[SMD=0.02,95%CI(0.00,0.03),P=0.02];③提示抗阻训练有利于维持绝经后妇女骨质疏松患者的骨密度水平,可以作为绝经后妇女骨质疏松运动治疗的重要组成部分。     

骨髓间充质干细胞干预治疗骨质疏松症中的骨组织生物力学性能

目的以雷洛昔芬干预治疗骨质疏松为对照,用生物力学性能指标验证骨髓间充质干细胞(bone mesenchymal stem cells,BMSCs)干预治疗骨质疏松动物的效果。方法取6月龄雌性SD大鼠88只,随机分为骨质疏松动物模型组22只,正常对照组22只,雷洛昔芬干预组22只,骨髓间充质干细胞干预组22只。以摘除大鼠卵巢的方法建立骨质疏松动物模型。动物饲养4周后,分别以骨髓间充质干细胞和雷洛昔芬对骨质疏松动物进行干预治疗。于给药6周后检测各组大鼠血清Ca、P、碱性磷酸酶(alkaline phosphatase,ALP),并取胫骨进行剪切实验,取股骨进行冲击实验,测试肱骨的骨密度(bone mineral density,BMD)。结果骨髓间充质干细胞干预组肱骨BMD,血清Ca、ALP,胫骨各项剪切力学性能指标和股骨各项冲击力学性能指标大于模型组及雷洛昔芬干预组,其血清P小于模型组及雷洛昔芬干预组(P<0.05)。结论骨质疏松动物通过以骨髓间充质干细胞干预后,肱骨BMD,血清Ca、ALP,骨的强度和韧性可以得到一定恢复。     

Avoiding the under-diagnosis of low bone mineral density in Egyptian children with chronic medical conditions affecting bone health

Introduction

The International Society for Clinical Densitometry recommended that the lumbar spine and total body less head (TBLH) are the most accurate and reproducible skeletal sites for performing areal bone mineral density (BMD) measurements. Our objective is to evaluate the role of measurement of femoral neck BMD in avoiding the under-diagnosis of low BMD being a risk for fractures in subjects with chronic medical conditions that might affect bone health.

Material and methods

Subjects with chronic medical conditions that might affect bone health were studied (n = 468) and 36 healthy children were recruited as control subjects. Physical examinations, height, weight measurements and BMI were calculated. Dual-energy radiographic absorptiometry of the lumbar spine and femoral neck were measured.

Results

Bone mineral density z scores in both sites were significantly reduced in chronic patients, compared with control subjects. Prevalence of very low BMD z scores (–2 or more) using lumbar DXA, femoral DXA, and either of the sites were 1.38%, 3.37%, and 3.96%, respectively, while low BMD Z scores (–1 to less than –2) were 9.52%, 18.05% and 21.14% respectively.

Conclusions

We identified a significant decrease in both lumbar and femoral BMDs in studied children. Sometimes femoral BMD is decreased while lumbar BMD is still within the normal range. For this reason we recommend that, when technically feasible and there is no facility to measure TBLH, all those patients should have lumbar spine and femoral neck bone mineral density measurements to avoid under-diagnosis of low BMD being a risk for fractures.     

辛伐他汀和吉非罗齐对高脂血症伴骨量减少患者骨代谢和骨密度的影响

目的观察辛伐他汀和吉非罗齐对高胆固醇血症伴骨量减少患者骨代谢指标及骨密度的影响。方法高脂血症合并骨量减少患者128例,分两组后分别予以辛伐他汀和吉非罗齐治疗,并在治疗前及治疗后分别检测血脂、骨吸收标志物血清I型胶原羧基末端肽（sCTX）、骨形成标志物总骨Ⅰ型前胶原N端肽（P1NP）和桡骨远端骨密度（BMD）。结果辛伐他汀组平均治疗周期（10.24±1.89）个月,治疗后总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL-C）明显降低（P〈0.05）,同时sCTX降低（P〈0.01）,P1NP增高（P〈0.05）,BMD增加（P〈0.01）,而吉非罗齐治疗后虽TC、TG、LDL-C明显降低（P〈0.05）但sCTX、P1NP和BMD无明显变化。结论较大剂量辛伐他汀具有抑制骨吸收、增强骨形成和增加BMD的作用,可能与血脂水平降低无关。